UNSPSC 51282327: Erythromycin stearate

This classification denotes a macrolide antibiotic with the molecular formula C37H67NO13.C18H36O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LXW024X05M, chemically known as stearic acid, compd. with erythromycin (1:1) but more generally known as erythromycin stearate, which bears US NIH Compound Identifier 12559. European Medicines Agency schedules Erythromycin stearate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01946MIG.

UNSPSC 51282327 Erythromycin stearate, a Commodity-tier code, shows limited recent activity directly aligned with its nominal scope; the recent opportunities posted under this code procure pharmaceuticals and medical supplies more broadly than the single active ingredient that names the code. State and local governments soliciting under this code are acquiring multi-source generic pharmaceuticals, over-the-counter products, naloxone and drug deactivation systems, and emergency medical supplies for use by health departments, fire rescue divisions, and pharmacy benefit programs. The issuing bodies include state health agencies (Texas Health and Human Services Commission), multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local members across multiple jurisdictions including Oregon), county health departments (Seminole County, Florida), and municipal fire and rescue divisions (City of Tampa). These jurisdictions are consolidating pharmaceutical procurement through established wholesaler networks and direct-to-manufacturer relationships rather than purchasing single active ingredients in isolation.

Recent opportunities span multiple regions and procurement vehicles. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products due March 26, 2026, requiring pricing by May 15, 2026 and effective July 1, 2026, with a two-year initial term and optional extensions. The Texas Health and Human Services Commission posted an RFI in April 2026 exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. Seminole County, Florida released IFB 60459723LAS on June 30, 2026 for naloxone and drug deactivation systems (1,900 units of naloxone and 800 systems annually) due July 26, 2023, with quarterly deliveries to the county health building. The City of Tampa issued ITB 26P00145 in March 2026 for 169 line items of medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000, with a sheltered small local business enterprise (SLBE) set-aside and a 5 percent SLBE bid discount capped at $10,000. The code sees activity concentrated in the Southeast (Florida) and Upper Midwest (Minnesota, Oregon), with recent procurement focused on aggregated volume and standardized product specifications rather than ingredient-level sourcing.